In the Spotlight

Read interviews to oncology professionals and other stakeholders who have made a remarkable contribution to cancer treatment.

Prevention and early detection are pivotal in LMICs, but not enough

Prevention and early detection are pivotal in LMICs, but not enough

While locally tailored cancer screening programmes, particularly for cervical cancer, are showing encouraging results in some areas with limited resources, cancer care is still suffering some bottlenecks due to lack of training for healthcare staff and shortages of medicines

Prevention, the key to make cancer care sustainable

Prevention, the key to make cancer care sustainable

Medical oncologists have traditionally played a marginal role in helping drive the adoption of preventive lifestyles, “but now it is time to strengthen our commitment” says ESMO President

Vaccinate cancer patients against COVID-19: experts address major uncertainties

Vaccinate cancer patients against COVID-19: experts address major uncertainties

At an ESMO Live Roundtable, a panel of experts discussed the benefits and risk of COVID-19 vaccination in patients with cancer, the practicalities of vaccinating those undergoing immunosuppressant treatment and the potential advantages and disadvantages of flexible dosing intervals.

Cancer screening programmes, a long road back to normal

Cancer screening programmes, a long road back to normal

In many countries, cancer screening activities are still suffering a complete shutdown, and according to public policy experts this may limit opportunities of a timely diagnosis especially to socio-economically vulnerable populations.
Is COVID-19 turning back the clock for patient empowerment?

Is COVID-19 turning back the clock for patient empowerment?

After years of progress in empowering patients with cancer to play a more active role in their care, the COVID-19 pandemic is leaving many feeling anxious with little control over if, when or how they will receive a diagnosis or treatment. 
Increased bureaucracy downgrades efficiency in cancer research

Increased bureaucracy downgrades efficiency in cancer research

Nearly 20 years since the first steps to harmonise clinical trial regulations across Europe, bureaucracy is now stifling research in oncology. A newly established ESMO Clinical Research Observatory (ECRO) Task Force identifies priorities for action.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.